Literature DB >> 7945480

A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children.

L G Rider1, F W Miller, I N Targoff, D D Sherry, E Samayoa, M Lindahl, M H Wener, L M Pachman, P H Plotz.   

Abstract

OBJECTIVE: Myositis-specific autoantibodies (MSA) define relatively homogeneous clinical and immunogenetic patient groups in adults with idiopathic inflammatory myopathies (IIM). This study explores the usefulness of MSA in defining groups of children with myositis.
METHODS: Sera from 77 children with myositis and other connective tissue diseases were tested for MSA by immunoprecipitation and immunodiffusion. Clinical data were collected and analyzed.
RESULTS: The MSA anti-PL-12 (alanyl-transfer RNA synthetase), anti-Jo-1 (histidyl-tRNA synthetase), anti-signal recognition particle, and anti-Mi-2 were each identified in the sera of 12 children with IIM. In these patients, the clinical manifestations, disease courses, and responses to therapy closely resembled those in adults with the same autoantibodies.
CONCLUSION: These observations suggest that the clinical syndromes defined by particular MSA are similar in children and adults with IIM. By defining similar clinical syndromes in children who have MSA, this study provides a basis for future studies of MSA in the idiopathic inflammatory myopathies of childhood, which may be useful in predicting the clinical courses of a subset of these patients and improving their therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945480     DOI: 10.1002/art.1780371019

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

Review 1.  Myositis-specific autoantibodies: detection and clinical associations.

Authors:  Sander H J van Dooren; Walther J van Venrooij; Ger J M Pruijn
Journal:  Auto Immun Highlights       Date:  2011-03-23

2.  Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.

Authors:  Altaf Hussain; Amit Rawat; Ankur Kumar Jindal; Anju Gupta; Surjit Singh
Journal:  Rheumatol Int       Date:  2017-03-22       Impact factor: 2.631

Review 3.  Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.

Authors:  L M Pachman; T O Fedczyna; T S Lechman; J Lutz
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 4.  Treatment of Juvenile Dermatomyositis: An Update.

Authors:  Charalampia Papadopoulou; Lucy R Wedderburn
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

5.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

6.  Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

Authors:  K Mizuno; A Yachie; S Nagaoki; H Wada; K Okada; M Kawachi; T Toma; A Konno; K Ohta; Y Kasahara; S Koizumi
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

Review 7.  Laboratory evaluation of the inflammatory myopathies.

Authors:  L G Rider; F W Miller
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

Review 8.  Juvenile dermatomyositis: advances in pathogenesis, evaluation, and treatment.

Authors:  Adam M Huber
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 9.  The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes.

Authors:  L G Rider; K Nistala
Journal:  J Intern Med       Date:  2016-03-30       Impact factor: 8.989

10.  Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

Authors:  H Gunawardena; L R Wedderburn; H Chinoy; Z E Betteridge; J North; W E R Ollier; R G Cooper; C V Oddis; A V Ramanan; J E Davidson; N J McHugh
Journal:  Arthritis Rheum       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.